|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 202.5 USD | +0.23% |
|
+6.27% | -21.76% |
| Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
| Apr. 25 | Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305 | MT |
Biogen Inc. revises revenue guidance for the full year 2022. The company now expects revenue of $10.0 to $10.15 billion against previous forecast of $9.9 to $10.1 billion.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.76% | 29.48B | |
| -4.88% | 87.53B | |
| +2.63% | 40.42B | |
| +58.56% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +5.17% | 8.75B | |
| -7.49% | 7.99B |
BIOGEN INC. 
